| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on April 26, 2004
Accepted on October 5, 2004
Lipids, Lipoproteins, and Cardiovascular Risk Factors |
1 Department for Clinical and Chemical Laboratory-Diagnostic, Hospital Lainz, Vienna, Austria
2 Department of Internal Medicine IV, Division of Diabetology and Rheumatology, Wilhelminenspital, Vienna, Austria
3 Ludwig Bolzmann Institute for Metabolic Diseases and Nutrition and Department of Internal Medicine III, Division of Metabolic Diseases and Nephrology, Hospital Lainz, Vienna, Austria
4 Department of Internal Medicine V, Division of Cardiology, Hospital Lainz, Vienna, Austria
5 Department of Surgery, SMZO, Vienna, Austria
* To whom correspondence should be addressed. E-mail: katharina.hermann{at}wienkav.at.
Background: Mild stages of heart failure might be difficult to diagnose in severely obese individuals with a body mass index (BMI) >40 kg/m2. Measurement of the N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) is feasible for detecting cardiac impairment. The aims of our study were to measure NT-proBNP in plasma of severely obese patients and to compare the results with results for patients in different stages of manifest cardiac dysfunction.
Methods: In 61 severely obese individuals (median BMI, 43.2 kg/m2) and 96 nonobese patients with existing heart failure [classified into New York Heart Association (NYHA) classes I-IV], NT-proBNP was measured in the fasting condition. A medical history, physical examination, electrocardiography, blood chemistry, and chest x-ray were performed in the obese group. In addition, echocardiography was performed in the NYHA group.
Results: In obese individuals, NT-proBNP was increased to a median of 356 (interquartile range, 221-458) pmol/L [854 (530-1099) ng/L] and was comparable (P >0.05) to the median value for NYHA I patients {289 (258-451) pmol/L [694 (619-1082) ng/L]}, but was significantly lower than in the other NYHA groups (P <0.001 for each).
Conclusion: The prognostic relevance of increased NT-proBNP for risk of developing cardiac insufficiency in severely obese patients needs to be further evaluated.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  P. Ray, S. Delerme, P. Jourdain, and C. Chenevier-Gobeaux Differential diagnosis of acute dyspnea: the value of B natriuretic peptides in the emergency department QJM, July 29, 2008; (2008) hcn080v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. S. Apple, A. H.B. Wu, A. S. Jaffe, M. Panteghini, R. H. Christenson, NACB COMMITTEE MEMBERS, R. H. Christenson, F. S. Apple, C. P. Cannon, G. Francis, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biomarkers of Heart Failure Circulation, July 31, 2007; 116(5): e95 - e98. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Carrillo-Jimenez, S. Borzak, and C. H. Hennekens Brain Natriuretic Peptide: Clinical and Research Challenges Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 85 - 88. [Abstract] [PDF]
|
|
|
|
 |
|
 A. E. Malavazos, L. Morricone, A. Marocchi, F. Ermetici, B. Ambrosi, and M. M. Corsi N-terminal pro-B-type natriuretic Peptide and echocardiographic abnormalities in severely obese patients: correlation with visceral fat. Clin. Chem., June 1, 2006; 52(6): 1211 - 1213. [Full Text] [PDF]
|
|
|
|
|
|
J. V. St. Peter, G. G. Hartley, M. M. Murakami, and F. S. Apple B-Type Natriuretic Peptide (BNP) and N-Terminal Pro-BNP in Obese Patients without Heart Failure: Relationship to Body Mass Index and Gastric Bypass Surgery Clin. Chem., April 1, 2006; 52(4): 680 - 685. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
